Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5201-5206

  Izumll, Kouji ^a   Kadono, Yoshifumi ^a   Shima, Takashi ^a   Konaka, Hiroyuki ^a   Mizokami, Atsushi ^a   Eitetsu, K O H ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Castration resistant prostate cancer; Ethinylestradiol; Prostate specific antigen

Indexed keywords

ETHINYLESTRADIOL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANOREXIA; ARTICLE; CASTRATION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FOLLOW UP; HEART FAILURE; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RETROSPECTIVE STUDY; SIDE EFFECT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; ETHINYL ESTRADIOL; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE;

EID: 78751524875     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765-781, 2010.
3. Petrylak DP: Chemotherapy for advanced hormone refractory prostate cancer. Urology 54(6A Suppl): 30-35, 1999.
4. Oh WK: Chemotherapy for patients with advanced prostate carcinoma. A new option for therapy. Cancer 88(12 Suppl): 3015-3021, 2000.
5. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T and Ito H: Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171(2 Pt 1): 679-683, 2004.
6. Hirano D, Minei S, Kishimoto Y, Yamaguchi K, Hachiya T, Yoshida T, Yoshikawa T, Endoh M, Yamanaka Y, Yamamoto T, Satoh Y, Ishida H, Okada K and Takimoto Y: Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int 75: 43-49, 2005.
7. Nishimura K. Nonomura N. Satoh E. Harada Y. Nakayama M. Tokizane T. Fukui T. Ono Y. Inoue H. Shin M. Tsujimoto Y. Takayama H. Aozasa K. Okuyama A. Potential mechanism for the effects of dexamenthasone on growth of androgen-independent prostate cancer Journal of the National Cancer Institute 2001 93 22 1739-1746 7 Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K and Okuyama A: Potential mechanism for the effects of dexamethasone on growth of androgenindependent prostate cancer. J Natl Cancer Inst 93: 1739-1746, 2001. (Pubitemid 33130263)
8. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET and Namiki M: Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor-β 1associated osteoblastic changes. Prostate 69: 1222-1234, 2009.
9. Izumi K, Mizokami A, Shima T, Narimoto K, Sugimoto K, Kobori Y, Maeda Y, Konaka H, Koh E and Namiki M: Preliminary results of tranilast treatment for patients with advanced castration-resistant prostate cancer. Anticancer Res 30: 3077-3081, 2010.
10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA; TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004.
12. Langeveld JW, Lycklama à Nijeholt AA and Jonas U: Oestrogen in the treatment of prostatic carcinoma. What is the safe and effective dose of ethinyloestradiol? Br J Urol 63: 76-79, 1989.
13. Dörner G, Schnorr D, Stahl F and Rohde W: Successful treatment of prostatic cancer with the orally active depot estrogen ethinylestradiol sulfonate (Turisteron). Exp Clin Endocrinol 56: 190-196, 1985.
14. Di Silvério F and Sciarra A: Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation-refractory prostate cancer. J Urol 170: 1812-1816,2003.
15. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A and Hussain M: Prostate Cancer Clinical Trials Working Group: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008.
16. Yagoda A. Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 1993 71 3 SUPPL. 1098-1109 16 Yagoda A and Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71: 1098-1109,1993. (Pubitemid 23049638)
17. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J Clin Oncol 25: 1496-1501, 2010.
18. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M and Sawyers CL: Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446, 2010.
19. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS and Fine RL: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88: 908-917, 1996.